Media

Strongbridge Biopharma plc Announces Acquisition of U.S. Rights to KEVEYIS® From Taro

Strongbridge Biopharma plc Announces $35 Million Equity Financing

Nexstim Plc receives FDA’s response to the proposed limited size stroke trial plan

Björn Westberg to join BONESUPPORT™ as Chief Financial Officer

GenSight Biologics reports sustained visual acuity gain at 78 weeks in its Phase I/II Study with GS010 for the treatment of Leber’s Hereditary Optic Neuropathy (LHON)

Cerenis Therapeutics Receives FDA IND Approval to Begin Studies with CER-209 in NAFLD and NASH

BONESUPPORT confirms election of Dr. Håkan Björklund as Chairman of the Board

Orexo appeal Zubsolv® US district court decision

Nordic Nanovector – Private placement successfully completed

Altimmune Announces Acceptance of HepTcell Abstract for Presentation at BSI/NVVI Congress 2016